BiotechTube

Fevipiprant 150 mg + Fevipiprant 450 mg + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasal Polyps

Conditions

Nasal Polyps

Trial Timeline

Mar 26, 2019 → Jun 10, 2020

NCT ID
NCT03681093

About Fevipiprant 150 mg + Fevipiprant 450 mg + Placebo

Fevipiprant 150 mg + Fevipiprant 450 mg + Placebo is a phase 3 stage product being developed by Novartis for Nasal Polyps. The current trial status is completed. This product is registered under clinical trial identifier NCT03681093. Target conditions include Nasal Polyps.

What happened to similar drugs?

8 of 20 similar drugs in Nasal Polyps were approved

Approved (8) Terminated (3) Active (11)
✅Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mgJohnson & JohnsonApproved
✅Budesonide NasalJohnson & JohnsonApproved
✅mometasone furoateMerckApproved
✅Dupilumab SAR231893SanofiApproved
✅DupilumabSanofiApproved
✅Dupilumab + Omalizumab + PlaceboSanofiApproved
✅Dupilumab Prefilled SyringeRegeneron PharmaceuticalsApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03681093Phase 3Completed

Competing Products

20 competing products in Nasal Polyps

See all competitors
ProductCompanyStageHype Score
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
31
Rabeprazole 20 mg twice a day for 90-day period treatmentEisaiPhase 2
35
High dose of methotrexate + Gemcitabine + Pegaspargase + DexamethasoneEli LillyPhase 2
31
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mgJohnson & JohnsonApproved
43
xylo+dex nasal spray (0.1 mg+5 mg/dose) + NasicJohnson & JohnsonPhase 3
40
Budesonide NasalJohnson & JohnsonApproved
47
Diphenhydramine hydrochlorideJohnson & JohnsonPhase 1
29
SHR-1210Jiangsu Hengrui MedicinePhase 2
31
Experimental: Tezepelumab + Mometasone furoate or equivalent intranasal corticosteroidAstraZenecaPhase 3
40
Benralizumab 30 mg + Matched placeboAstraZenecaPhase 3
32
Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone FuroateAstraZenecaPhase 3
40
Benralizumab + PlaceboAstraZenecaPhase 3
40
Pembrolizumab + Cisplatin + Docetaxel + CarboplatinMerckPhase 2
42
mometasone furoateMerckApproved
35
Omalizumab + PlaceboNovartisPhase 2
35
Omalizumab + PlaceboRochePhase 3
40
Omalizumab + PlaceboRochePhase 3
40
Omalizumab + PlaceboRochePhase 3
40
carfilzomibAmgenPhase 1
29